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Objectives The study sought to contrast risk profiles and compare outcomes of patients with severe aortic stenosis (AS) and
coronary artery disease (CAD) who underwent aortic valve replacement (AVR) and coronary artery bypass graft-
ing (ASCABG) with those of patients with isolated AS who underwent AVR alone.
Background In patients with severe AS, CAD is often an incidental finding with underappreciated survival implications.
Methods From October 1991 to July 2010, 2,286 patients underwent AVRCABG and 1,637 AVR alone. A propensity
score was developed and used for matched comparisons of outcomes (1,082 patient pairs). Analyses of long-
term mortality were performed for each group, then combined to identify common and unique risk factors.
Results Patients with ASCAD versus isolated AS were older, more symptomatic, and more likely to be hypertensive,
and had lower ejection fraction and greater arteriosclerotic burden but less severe AS. Hospital morbidity and
long-term survival were poorer (43% vs. 59% at 10 years). Both groups shared many mortality risk factors; how-
ever, early risk among ASCAD patients reflected effects of CAD; late risk reflected diastolic left ventricular dys-
function expressed as ventricular hypertrophy and left atrial enlargement. Patients with isolated AS and few co-
morbidities had the best outcome, those with CAD without myocardial damage had intermediate outcome
equivalent to propensity-matched isolated AS patients, and those with CAD, myocardial damage, and advanced
comorbidities had the worst outcome.
Conclusions Cardiovascular risk factors and comorbidities must be considered in managing patients with severe AS. Patients
with severe AS and CAD risk factors should undergo early diagnostics and AVRCABG before ischemic myocar-
dial damage occurs. (J Am Coll Cardiol 2013;61:837–48) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.049Patients treated for severe aortic stenosis (AS) constitute a
heterogeneous population ranging from young patients with
isolated bicuspid valve disease to elderly patients with
degenerative disease complicated by comorbidities. The
most common comorbidity importantly influencing out-
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accepted October 16, 2012.comes after aortic valve replacement (AVR), affecting a
third of patients and half of those above age 70 years, is
coronary artery disease (CAD) (1–3). Current guidelines
recommend bypass of all significant stenoses at the time of
AVR, with evidence level C (4); however, addition of
coronary artery bypass grafting (CABG) to AVR is associ-
ated with elevated short- and long-term mortality (5–10).
This association may be causal (e.g., by increasing myocar-
dial ischemic time) (11) or simply a marker for a high-risk
patient profile. Clarifying this may lead to more targeted
diagnostics, therapy, and chronic disease management.
See page 849
To provide insight into severe AS with and without CAD
and current treatment and patient outcomes, we contrasted
risk profiles, compared outcomes, and identified risk factors
for mortality. To accomplish these objectives, we studied a
large group of patients who had routine pre-operative
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Coronary Artery Disease and Aortic Stenosis February 26, 2013:837–48coronary angiography before
AVR and received the most
common AVR device implanted
at our institution, with or with-
out CABG. We sought to iden-
tify risk factors both unique to
AS and ASCAD patients and
ones in common.
For fair comparison of out-
comes in comparable patients,
we used propensity score–based
matching. Characteristics of AS
or ASCAD patients who could
not be propensity matched pro-
vided insight into the profile of a
subgroup of patients expected to have excellent long-term
survival after operation, and another with substantially
poorer survival. We believe these investigations provide
both support for current guidelines as well as information
useful for amplifying and refining them.
Methods
Patients. From October 1991 to July 2010, 4,372 patients
at Cleveland Clinic underwent primary AVR with a single
type of bovine pericardial prosthesis (Carpentier-Edwards
PERIMOUNT, Edwards Lifesciences Corporation, Irvine,
California) for severe AS (aortic valve area 1 cm2 on
ransthoracic echocardiography [TTE]), with or without
ABG. During this period, it was our policy to perform
oronary angiography on all patients considered for AVR.
resence of CAD was defined as at least 1 epicardial artery
left main trunk, left anterior descending coronary artery,
eft circumflex coronary artery, and right coronary artery)
ith at least 50% stenosis or history of percutaneous
oronary intervention. Groups were defined on the basis of
he presence of CAD and CABG. Thus, we excluded 22
atients with 50% stenosis in all coronary vessels who
nderwent AVR and CABG, as well as 427 patients with
0% or greater coronary stenosis who underwent AVR
lone. Remaining study groups consisted of 1,637 patients
ith severe AS without CAD who underwent AVR alone
isolated AS group) and 2,286 patients with severe AS and
AD who underwent AVR and CABG (ASCAD
roup) (Online Fig. 1). Patients with missing coronary
tenosis data, prior cardiac surgery, infective endocarditis,
heumatic valve disease, indications for AVR other than
S, and those who underwent thoracic aorta or valvar
perations other than mitral or tricuspid procedures for
unctional or ischemic regurgitation were excluded. Pa-
ient characteristics are presented in Table 1.
Pre-operative, operative, and post-operative variables,
ncluding echocardiographic variables, were retrieved from
rospective databases approved for use in research by the
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
LA  left atrial
LV  left ventricular
TTE  transthoracic
echocardiographynstitutional Review Board, with patient consent waived.re-operative echocardiography. Pre-operative measure-
ents were retrieved from the TTE performed nearest to,
ut preceding, the operation. Median interval between TTE
nd surgery was 7 days, and 3,020 patients (81%) under-
ent AVR within 30 days. Left ventricular (LV) mass
as calculated using the formula validated by Devereux et
l. (12), indexed to body surface area. Peak instantaneous
ortic valve gradients were calculated from Doppler
elocity. Pre-operative TTE measurements are summa-
ized in Table 2.
ndpoints. Our primary endpoint was all-cause mortality
rom date of operation. Patients were systematically fol-
owed at 2 years, then every 5 years by telephone or mailed
uestionnaire. This active follow-up was supplemented with
assive Social Security Death Master File data. Follow-up
nformation was unavailable for 60 patients (1.5%). Median
ollow-up was 4.7 years; 25% of patients were followed more
han 8 years and 10% more than 11 years; 21,005 patient-
ears of data were available for analysis.
Survival was estimated nonparametrically by the Kaplan-
eier method and parametrically by a multiphase hazard
odel (13). Parametric modeling was used to resolve the
umber of phases of instantaneous risk of death (hazard
unction) and to estimate shaping parameters. These were
odeled separately for each group. As is characteristic of
ardiac surgery procedures, there was an initial phase of high
isk immediately after surgery that merged with a phase of
ower risk (14). The temporal decomposition of this phe-
omenon is illustrated in Online Figure 2, which shows
hat we term an early, rapidly declining hazard phase
tarting immediately after surgery, and a late rising hazard
hase, which cross at about 7 to 12 months. Factors
odulating each phase are expected to be quite different
nonproportional hazards), which is the motivation behind
he approach. Because the temporal decomposition pro-
uces hazard phases with little overlap, modulating factors
re processed simultaneously for all hazard phases (2 in this
ase).
Reference population survival estimates were generated
rom equations for the U.S. life tables for each patient
ccording to age, race, and sex. These were averaged overall
nd within subgroups of patients.
Secondary endpoints were in-hospital morbidities defined
y the Society of Thoracic Surgeons National Database.
ata analysis. PATIENT CHARACTERISTICS. Simple com-
parisons were made using Wilcoxon rank-sum nonparamet-
ric tests. When the frequency was 5, comparisons were
made using chi-square and Fisher’s exact tests.
Differences in pre-operative patient and echocardio-
graphic measures between isolated AS versus ASCAD
patients were analyzed by multivariable logistic regression
using variables listed in Online Appendix 1. CAD- and
CABG-related variables defined the ASCAD group, as
did history of myocardial infarction and coronary artery
stenosis variables; thus, we did not include them in the
modeling. Variable selection, with a p value of 0.05 for
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February 26, 2013:837–48 Coronary Artery Disease and Aortic Stenosisretention of variables, utilized bagging (15,16). Briefly,
automated stepwise variable selection was performed on 250
bootstrap samples, and frequency of occurrence of variables
related to procedure performed was ascertained by the
median rule (15). In doing this, it became apparent that a
number of continuous variables demonstrated a nonlinear
relationship to group membership. Therefore, to demon-
strate the shape of these relationships, we performed a
Random Forests classification analysis, using all variables
considered in the analysis, to produce nonparametric partial
dependency risk-adjusted graphs of the probability of being
in the ASCAD group as a function of these variables (see
Online Appendix 2 for details).
UNIQUE RISK FACTORS. To identify risk factors that may be
nique to isolated AS and ASCAD, separate parsimoni-
us risk factor models were developed using variables listed
n Online Appendix 1. Risk factors were then combined
rom the 2 parsimonious models (Online Tables 1a and 1b)
o create semisaturated models (Online Table 1c) for each
roup, with all factors identified in both analyses included.
n the basis of these, an overall model was constructed in
hich group-specific risk factors were incorporated as in-
eraction effects.
SURVIVAL ANALYSIS. Due to differences in underlying pa-
ient characteristics, propensity matching of isolated AS
ith ASCAD patients was employed (17). Multivariable
ogistic regression using pre-operative and procedure vari-
bles was used to identify factors associated with isolated AS
ersus ASCAD, as described in the Patient Characteris-
ics Subsection. After developing that parsimonious model,
dditional variables representing patient factors that might
elate to unrecorded selection factors were added (semisatu-
ated model; see Online Appendix 1). A propensity score
as calculated for each patient by solving the saturated
odel for the probability of being in the ASCAD group.
sing only propensity scores, 1,082 isolated AS patients
66%) were matched to ASCAD patients using a greedy
atching strategy (Tables 1 and 2, Online Fig. 3) (18,19).
solated AS patients whose propensity scores deviated more
han 0.10 in probability scale from those of ASCAD
atients were considered unmatched.
Survival was compared for propensity-matched patients
sing the log-rank test and contrasted with that of un-
atched isolated AS patients who did not fit the comor-
idity profile of ASCAD patients, and with unmatched
SCAD patients whose comorbidity profile did not fit
hat of isolated AS patients (19).
issing data. To account for missing values for some
ariables, 5-fold multiple imputation was performed (17)
sing a Markov Chain Monte Carlo technique (SAS
ROC MI in version 9.1, SAS, Inc., Cary, North Caro-
ina). Only covariables were imputed, not outcomes. Bootstrap
agging for variable selection, as described earlier, used 1
mputed dataset. Regression coefficients and their variance–
ovariance matrix for the final models were subsequentlystimated for each imputed dataset and combined using the
ethod of Rubin to produce the final estimates (17).
resentation. Continuous variables are summarized as
ean  SD and as equivalent 15th, 50th (median), and
85th percentiles when values are skewed. Categorical data
are summarized using frequencies and percentages. All
analyses were performed using SAS statistical software
(SAS version 9.1). Parametric survival estimates are accom-
panied by asymmetric 68% confidence limits, comparable to
1 standard error.
Results
Unadjusted outcome comparisons. Compared with iso-
lated AS patients, ASCAD patients had worse early and
late unadjusted survival (97.6% vs. 98.7%, 91% vs. 94%, 83%
vs. 90%, and 43% vs. 59% at 30 days and 1, 5, and 10 years,
respectively) (Fig. 1). They also experienced greater post-
operative morbidity with significantly more septicemia
(2.8% vs. 1.6%), renal failure (6.4% vs. 3.5%), prolonged
ventilation (14% vs. 6.4%), and atrial fibrillation (36% vs.
32%) (Online Table 2).
Patient characteristics. Compared with isolated AS pa-
tients, ASCAD patients tended to be older men with
more severe symptoms; they were more likely to have LV
dysfunction and comorbidities, including vasculopathies,
systolic hypertension, diabetes, and anemia (Table 3). In
contrast, isolated AS patients were more likely young and
overweight with more severe AS, bicuspid valves, diastolic
hypertension, less LV hypertrophy, and smaller left atria
compared with ASCAD patients.
Unique risk factors. In both groups, patients who were
elderly and more symptomatic had increased risk of death
early after surgery (Table 4). Late risk was associated with
smoking and LV dysfunction. Some of these common
factors had statistically significant different strengths be-
tween groups, including higher creatinine levels in the early
hazard phase and older age and higher blood urea nitrogen
in the late hazard phase.
Unique to isolated AS patients was early mortality associated
with smaller LV diastolic volume and other systemic illnesses,
including anemia and liver dysfunction (see Table 4). The
status of the LV at time of surgery, notably presence of
severe LV hypertrophy and left atrial (LA) dilation, was
associated with increased late risk of death, with a more
pronounced effect in younger patients (Online Fig. 5).
Unique to ASCAD patients was early mortality asso-
ciated with more severe LV systolic dysfunction and aortic
or tricuspid valve regurgitation (see Table 4). In contrast to
the isolated AS group, prior myocardial infarction, insulin-
dependent diabetes, dialysis, and anemia were associated
with increased risk of late death. Addition of an atrial
fibrillation procedure or patent foramen ovale suture closure
was associated with increased risk of death. Internal thoracic
artery grafts used for CABG were associated with decreased
mortality.
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Coronary Artery Disease and Aortic Stenosis February 26, 2013:837–48Patient Characteristics and Operative Details in Those With Severe AS Alone (Isolated AS) Versus ASCADTable 1 Patient Characteristics and Operative Details in Those With Severe AS Alone (Isolated AS) Versus ASCAD
Characteristic
Overall Propensity Matched
Isolated AS
(n  1,637)
ASCAD
(n  2,286)
p Value
Isolated AS
(n  1,082)
ASCAD
(n  1,082)
p Valuen*
No. (%) or
Mean  SD n*
No. (%) or
Mean  SD n*
No. (%) or
Mean  SD n*
No. (%) or
Mean  SD
Demography
Female 1,637 769 (47) 2,286 774 (34) 0.0001 1,082 450 (42) 1,082 458 (42) 0.7
Age, yrs 1,637 70 11 2,286 75 8.1 0.0001 1,082 73 9.4 1,082 73 8.6 0.5
BSA, m2 1,607 2.0 0.27 2,263 2.0 0.25 0.03 1,059 2.0 0.26 1,066 2.0 0.26 0.04
Symptoms
Pre-operative NYHA
functional class
1,607 2,263 0.0001 1,059 1,066 0.9
I 395 (25) 346 (15) 222 (21) 227 (21)
II 835 (52) 1,180 (52) 558 (53) 559 (52)
III 325 (20) 573 (25) 233 (22) 239 (22)
IV 52 (3.2) 164 (7.2) 46 (4.3) 41 (3.8)
Canadian Angina class 1,231 1,946 0.0001 833 882 0.0001
0 537 (44) 624 (32) 366 (44) 307 (35)
I 391 (32) 469 (24) 275 (33) 230 (26)
II 260 (21) 656 (34) 163 (20) 286 (32)
III 39 (3.2) 162 (8.3) 26 (3.1) 53 (6.01)
IV 4 (0.32) 35 (1.8) 3 (0.36) 6 (0.68)
Syncope 1,271 176 (14) 1,892 271 (14) 0.7 860 120 (14) 860 130 (15) 0.5
Dyspnea on exertion 1,170 613 (52) 1,771 897 (51) 0.4 789 418 (53) 800 410 (51) 0.5
Shortness of breath 1,169 687 (59) 1,772 976 (55) 0.05 788 451 (57) 801 463 (58) 0.8
Paroxysmal nocturnal
dyspnea
1,168 84 (7.2) 1,771 171 (9.7) 0.02 787 61 (7.8) 800 69 (8.6) 0.5
Orthopnea 1,168 150 (13) 1,772 231 (13) 0.9 787 105 (13) 801 111 (14) 0.8
Valve pathology
Pure aortic stenosis 1,603 1,203 (75) 2,219 1,682 (76) 0.6 1,054 778 (74) 1,056 794 (75) 0.5
Mixed aortic stenosis/
regurgitation
1,603 332 (21) 2,219 468 (21) 0.8 1,054 223 (21) 1,056 225 (21) 0.9
Bicuspid aortic valve 1,637 659 (40) 2,286 411 (18) 0.0001 1,082 298 (28) 1,082 296 (27) 0.9
Mitral valve regurgitation
severity
1,509 2,096 0.0001 982 977 0.9
None 811 (54) 923 (44) 478 (49) 490 (50) 9
Mild 419 (28) 637 (30) 294 (30) 287 (29)
Moderate 218 (14) 372 (18) 158 (16) 150 (15)
Moderately severe 50 (3.3) 133 (6.3) 43 (4.4) 41 (4.2)
Severe 11 (0.73) 31 (1.5) 9 (0.92) 9 (0.92)
Tricuspid valve
regurgitation severity
1,518 2,095 0.02 990 980 0.4
None 1,020 (67) 1,317 (63) 643 (65) 624 (64)
Mild 318 (21) 462 (22) 211 (21) 219 (22)
Moderate 120 (7.9) 220 (11) 91 (9.2) 87 (8.9)
Moderately severe 42 (2.8) 74 (3.5) 31 (3.1) 42 (4.3)
Severe 18 (1.2) 22 (1.1) 14 (1.4) 8 (0.82)
Coronary artery disease
Number of systems
diseased 50%
1,629 2,284 0.0001 1,076 1,080 0.0001
0 1,629 (100) 105 (4.6) 1,076 (100) 73 (6.8)
1 0 (0) 803 (35) 0 (0) 473 (44)
2 0 (0) 745 (33) 0 (0) 322 (30)
3 0 (0) 631 (28) 0 (0) 212 (20)
LMT disease 50% 1,533 0 (0) 2,032 296 (15) 0.0001 1,001 0 (0) 973 107 (11) 0.0001
LAD system disease 50% 1,595 0 (0) 2,249 1,624 (72) 0.0001 1,049 0 (0) 1,062 709 (68) 0.0001
LCx system disease 50% 1,561 0 (0) 2,189 1,134 (52) 0.0001 1,027 0 (0) 1,036 455 (44) 0.0001
RCA system disease 50% 1,637 0 (0) 2,286 1,428 (62) 0.0001 1,082 0 (0) 1,082 589 (54) 0.0001Continued on the next page
d circumfl
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among propensity-matched isolated AS and ASCAD
patients (93% vs. 93%, 80% vs. 80%, and 55% vs. 50% at 1,
5, and 10 years, respectively) (Fig. 2). Within the isolated
ContinuedTable 1 Continued
Characteristic
Overall
Isolated AS
(n  1,637)
ASCAD
(n  2,286)
n*
No. (%) or
Mean  SD n*
No. (%)
Mean 
Cardiac comorbidity
Previous myocardial
infarction
1,637 126 (7.7) 2,286 652 (2
Atrial fibrillation/flutter 1,458 114 (7.8) 2,009 204 (1
Complete heart
block/pacer
1,452 62 (4.3) 2,002 115 (5
Ventricular arrhythmia 1,492 167 (11) 2,074 274 (1
Heart failure 1,637 330 (20) 2,286 691 (3
Noncardiac comorbidity
Peripheral arterial disease 1,637 65 (4.0) 2,286 278 (1
Carotid disease 1,637 500 (31) 2,286 1,215 (5
Stroke 1,637 102 (6.2) 2,286 221 (9
Hypertension 1,637 1,063 (65) 2,286 1,811 (7
Insulin-treated diabetes 1,600 61 (3.8) 2,213 212 (9
Pharmacologically treated
diabetes
1,602 243 (15) 2,219 582 (2
BUN, mg·dl1 1,606 20 8.3 2,249 23
Creatinine, mg·dl1 1,606 1.03 0.45 2,235 1.2
Pre-operative renal dialysis 1,377 12 (0.87) 1,929 34 (1
COPD 1,637 201 (12) 2,286 327 (1
Smoking 1,630 803 (49) 2,266 1,247 (5
Cholesterol, mg·dl1 1,266 187 45 1,683 181
Triglycerides, mg·dl1 1,262 132 75 1,668 135
HDL cholesterol, mg·dl1 1,261 54 18 1,672 48
LDL cholesterol, mg·dl1 1,260 108 39 1,666 106
Bilirubin, mg·dl1 1,529 0.67 0.46 2,102 0.68
Hematocrit, % 1,551 39 5.4 2,124 38
Concomitant procedures
Mitral valve repair 1,637 22 (1.3) 2,286 77 (3
Tricuspid valve repair 1,637 33 (2.0) 2,286 53 (2
Aortic endarterectomy 1,637 49 (3.0) 2,286 125 (5
Any atrial fibrillation
procedure
1,637 97 (5.9) 2,286 143 (6
Septal myectomy 1,637 30 (1.8) 2,286 34 (1
ASD/PFO suture closure 1,637 27 (1.6) 2,286 37 (1
Aortic valve prosthesis
Valve size, mm 1,637 2,286
19 240 (15) 350 (1
21 483 (30) 666 (2
23 532 (32) 786 (3
25 303 (18) 394 (1
27 68 (4.2) 79 (3
29 11 (0.67) 11 (0
Standardized size (z value) 1,605 0.42 0.99 2,262 0.41
*Patients with data available.
AS aortic stenosis; ASD/PFO atrial septal defect/patent foramen ovale; BSA body surface
isease; HDL high-density lipoprotein; LAD left anterior descending coronary artery; LCx left
ssociation; RCA  right coronary artery.AS group, matched patients had a significantly lowersurvival than unmatched patients with few comorbidities
(93% vs. 97%, 80% vs. 90%, and 55% vs. 70% at 1, 5, and
10 years, respectively) (Online Tables 3a and 3b, Fig. 2).
Conversely, ASCAD matched patients had significantly
Propensity Matched
p Value
Isolated AS
(n  1,082)
ASCAD
(n  1,082)
p Valuen*
No. (%) or
Mean  SD n*
No. (%) or
Mean  SD
0.0001 1,082 117 (11) 1,082 112 (10) 0.7
0.02 957 90 (9.4) 927 79 (8.5) 0.5
0.05 951 55 (5.8) 926 51 (5.5) 0.8
0.07 982 121 (12) 967 130 (13) 0.5
0.0001 1,082 257 (24) 1,082 248 (23) 0.6
0.0001 1,082 57 (5.3) 1,082 65 (6.0) 0.5
0.0001 1,082 424 (39) 1,082 430 (40) 0.8
0.0001 1,082 85 (7.9) 1,082 78 (7.2) 0.6
0.0001 1,082 782 (72) 1,082 798 (74) 0.4
0.0001 1,055 55 (5.2) 1,056 53 (5.0) 0.8
0.0001 1,055 199 (19) 1,059 201 (19) 0.9
0.0001 1,057 21 8.7 1,062 21 9.6 0.6
0.0001 1,058 1.08 0.47 1,053 1.08 0.51 0.6
0.03 898 9 (1.0) 908 14 (1.5) 0.3
0.07 1,082 132 (12) 1,082 149 (14) 0.3
0.0004 1,077 536 (50) 1,077 529 (49) 0.8
0.0002 813 183 44 834 186 45 0.2
0.2 810 132 74 829 134 77 0.4
0.0001 808 51 16 830 51 15 0.6
0.2 807 106 38 830 109 40 0.15
0.9 1,000 0.69 0.52 1,000 0.69 0.67 0.6
0.0001 1,017 38 5.5 1,010 38 5.5 0.6
0.0001 1,082 17 (1.6) 1,082 13 (1.2) 0.5
0.5 1,082 26 (2.4) 1,082 27 (2.5) 0.9
0.0002 1,082 37 (3.4) 1,082 40 (3.7) 0.7
0.7 1,082 74 (6.8) 1,082 71 (6.6) 0.8
0.4 1,082 21 (1.9) 1,082 26 (2.4) 0.5
0.9 1,082 16 (1.5) 1,082 18 (1.7) 0.7
0.5 1,082 1,082 0.4
163 (15) 190 (18)
312 (29) 319 (29)
353 (33) 316 (29)
200 (18) 207 (19)
50 (4.6) 44 (4.1)
4 (0.37) 6 (0.55)
0.8 1,059 0.42 0.99 1,066 1.42 1.01 0.9
UN blood urea nitrogen; CAD coronary artery disease; COPD chronic obstructive pulmonary
ex coronary artery; LDL low-density lipoprotein; LMT left main trunk; NYHA New York Heartor
SD
9)
0)
.7)
3)
0)
2)
3)
.7)
9)
.6)
6)
11
0.59
.8)
4)
5)
46
80
15
41
0.54
5.6
.4)
.3)
.5)
.3)
.5)
.6)
5)
9)
4)
7)
5)
.48)
0.95
area; Bhigher survival than unmatched patients with myocardial
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Coronary Artery Disease and Aortic Stenosis February 26, 2013:837–48damage and many comorbidities (93% vs. 89%, 78% vs.
67%, and 50% vs. 36% at 1, 5, and 10 years, respectively)
(Online Tables 4a and 4b, Fig. 2). Differences in survival
relate to the disparate patient profiles that resulted in
propensity matching intermediate profile groups (Fig. 3,
Table 1).
Post-operative in-hospital morbidity was similar among
matched patients, except for more prolonged ventilation in
ASCAD patients (Online Table 2).
Pre-Operative Echocardiographic MeasurementsTable 2 Pre-Operative Echocardiographic Measurements
Measurement
Overall
Isolated AS
(n  1,637)
ASCAD
(n  2,28
n* Mean  SD n* Mea
Aortic valve hemodynamics
Area, cm2 1,426 0.65 0.14 1,992 0.67
Mean gradient, mm Hg 1,468 52 16 2,042 45
Peak gradient, mm Hg 1,474 87 26 2,042 76
Left ventricle
Morphology
Posterior wall thickness, cm 1,430 1.3 0.24 1,894 1.3
Septal thickness, cm 1,440 1.5 0.29 1,915 1.5
Mass index, g·m2 1,398 128 42 1,863 134
End-diastolic diameter, cm 1,446 4.6 0.79 1,934 4.7
End-systolic diameter, cm 1,432 3.0 0.84 1,911 3.1
Function
Ejection fraction, % 1,509 55 11 2,134 51
Left atrium
Diameter, cm 1,352 4.1 0.76 1,836 4.3
*Patients with data available.
Abbreviations as in Table 1.
(1,
(7
(1,054)
(1,499)
(1,393)
(1,937)
Figure 1 Unadjusted Survival Among Patients After Surgery
Unadjusted survival among patients after surgery for isolated aortic stenosis (blue
sent Kaplan-Meier nonparametric estimates at yearly intervals, accompanied by ve
enclosed within dashed confidence bands equivalent to 1 standard error represeMatched and unmatched patient characteristics. Un-
matched patients within the isolated AS group, on average,
represent younger persons with mild symptoms and few to
no comorbidities (Fig. 4, Online Tables 3a and 3b). How-
ever, they had the most hemodynamically severe form of AS
among the groups, with high aortic valve gradients and a
predominance of bicuspid valves (65% matched vs. 28%
unmatched). They tended to have isolated AS, with few
having concomitant mitral or tricuspid valve disease. This
Propensity Matched
p Value
Isolated AS
(n  1,082)
ASCAD
(n  1,082)
p ValueD n* Mean  SD n* Mean  SD
4 0.0001 942 0.65 0.14 932 0.66 0.14 0.5
0.0001 969 50 16 957 49 16 0.4
0.0001 975 84 25 956 84 24 0.9
3 0.5 932 1.3 0.24 905 1.3 0.22 0.8
1 0.6 939 1.5 0.28 915 1.5 0.29 0.9
0.0001 908 132 43 886 131 42 0.6
1 0.0001 945 4.6 0.82 927 4.6 0.82 0.2
0 0.0001 940 3.0 0.86 920 3.0 0.85 0.2
0.0001 987 54 11 1,006 54 11 0.4
5 0.0001 887 4.2 0.75 857 4.2 0.75 0.4
Isolated AS 
(244)
(504)
(726)
(335)
AS+CAD
ted AS) versus AS with coronary artery disease (red; ASCAD). Symbols repre-
bars representing confidence limits equivalent to 1 standard error. Solid lines
rametric estimates.6)
n  S
 0.1
 16
 25
 0.2
 0.3
 41
 0.8
 0.9
 13
 0.7100)
79)
; isola
rtical
nt pa
. ††Log
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hemodynamically less severe AS, but significantly higher
prevalence of comorbid conditions, including vasculopa-
thies, stroke, hypertension, diabetes, and renal disease.
These matched patients also had worse LV systolic func-
tion, more heart failure, complete heart block, atrial fibril-
lation, and greater LV hypertrophy and LA dilation com-
pared with unmatched isolated AS patients.
In contrast, unmatched ASCAD patients represent the
opposite spectrum of disease severity. They tended to be
older males with the most severe symptoms and extensive
comorbidities (Fig. 4, and Online Tables 4a and 4b).
Unmatched ASCAD patients had the least severe AS;
however, they had the highest prevalence of CAD risk
factors among the groups, including vasculopathies, smok-
ing, hypertension, diabetes, and renal disease. They also had
more heart failure and LV dysfunction, the most severe LV
hypertrophy and dilation, and more ischemic mitral disease
and atrial fibrillation.
Discussion
Principal findings. Overall, ASCAD patients had
poorer short- and long-term prognosis than those with
isolated AS and more post-operative morbidity. Increased
mortality of ASCAD patients was associated with effects
of pre-existing ischemic myocardial damage and comorbidi-
ties. In contrast, prognosis for isolated AS patients was
Patient Variables Associated With Severe AS Alone (Isolated AS) VTable 3 Patient Variables Associated With Severe AS Alone (Is
Variable* Coefficient  SE
Higher likelihood of isolated AS
Larger BMI‡ 0.34 0.094
Shortness of breath 0.29 0.10
COPD 0.22 0.11
Higher aortic valve peak gradient§ 0.85 0.098
Bicuspid aortic valve 0.56 0.092
Tricuspid valve regurgitation 3/4 0.45 0.20
Higher diastolic blood pressure 0.20 0.085
Higher likelihood of ASCAD
Older age¶ 2.2 0.32
Male 0.78 0.087
Higher NYHA functional class 0.25 0.053
Lower ejection fraction# 0.42 0.12
Peripheral arterial disease 0.58 0.16
Carotid disease 0.63 0.078
Hypertension 0.54 0.088
Higher systolic blood pressure** 0.33 0.15
Diabetes 0.47 0.099
Lower hematocrit†† 0.90 0.28
Lower HDL‡‡ 0.60 0.14
Aorta procedure 0.43 0.19
*See Online Figure 4 for an illustration of the nature of the relationship of continuous variables to lik
‡(BMI/30)2, squared transformation. §(80/AV peak gradient), inverse transformation. (75/diast
fraction/55)2, squared transformation. **(Systolic blood pressure/135)2, squared transformation
AV  aortic valve; BMI  body mass index; CI  confidence interval; other abbreviations as inadversely influenced by the negative influence of LV hyper-trophy and diastolic dysfunction at operation. But further
analyses using propensity matching clearly identified dis-
tinct patient subgroups with differing prognosis. The first
comprised patients with isolated AS who had the best
outcome and whose survival was adversely affected by LV
hypertrophy and diastolic dysfunction. The second com-
prised patients with CAD without evidence of ischemic
myocardial damage. These patients had outcome similar to
those with isolated AS and similar non-CAD comorbidi-
ties. The third group comprised patients with severe
ASCAD and ischemic damage and multiple comorbidi-
ties, unlike patients with isolated severe AS. They had the
poorest survival, despite the least degree of AS.
Patient profiles. That patients with ASCAD were older
and more symptomatic with less severe AS, but more risk
factors for CAD than patients with isolated AS, has been
documented by others (3). Onset of symptoms likely results
from the combined effects of CAD and AS, resulting in
catheterization and earlier intervention for their valvar and
coronary diseases. This stands in contrast to milder, but
slowly developing symptoms more characteristic of patients
with isolated AS.
Unique risk factors. Patients with ASCAD display risk
profiles reflecting CAD (20–22). Survival is dominated by
comorbidities, particularly vasculopathy. Many of their risk
factors have been described by others (5,23,24), including
older age, more severe symptoms, vasculopathy, previous
stroke, diabetes, previous myocardial infarction, and renal
s ASCADd AS) Versus ASCAD
Odds Ratio (68% CI) p Value Reliability (%)†
—* 0.0003 82
1.3 (1.2–1.5) 0.006 97
1.2 (1.1–1.4) 0.05 41
—* 0.0001 100
1.8 (1.6–1.9) 0.0001 100
1.6 (1.3–1.9) 0.02 64
—* 0.02 74
—* 0.0001 89
2.2 (2.0–2.4) 0.0001 98
1.3 (1.2–1.4) 0.0001 99
—* 0.0005 98
1.8 (1.5–2.1) 0.0002 82
1.9 (1.7–2.03) 0.0001 100
1.7 (1.6–1.9) 0.0001 100
—* 0.03 74
1.6 (1.4–1.8) 0.0001 100
—* .001 81
—* 0.0001 100
1.5 (1.3–1.9) 0.02 81
of having coronary artery disease. †Percent of times variables appeared in 250 bootstrap models.
od pressure)2, inverse squared transformation. ¶Log(age), logarithmic transformation. #(Ejection
(hematocrit), logarithmic transformation. ‡‡Log(HDL), logarithmic transformation.
.ersuolate
elihood
olic blodisease.
ss
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dominated by secondary effects of AS on myocardium,
notably LV hypertrophy and diastolic dysfunction (25).
Severe LV hypertrophy only partly regresses after AVR
Overall Model for Incremental Risk Factors for Death After ProceduTable 4 Overall Model for Incremental Risk Factors for Death A
Common
Risk Factor Coefficient  SE
Early hazard phase
Isolated AS 3.7 0.89 
ASCAD
LMT stenosis 70%
LAD stenosis 70%
RCA stenosis 50%
LCx stenosis 0%
Older age* 1.9 0.34 
Larger height/weight ratio
NYHA functional class III/IV 0.66 0.13 
Heart failure
Aortic valve regurgitation 3/4
Tricuspid valve regurgitation 4
Lower LV diastolic volume†
Lower ejection fraction
Lower HDL‡
Carotid disease (less risk)
COPD
Treated diabetes
Higher creatinine§
Higher bilirubin
Lower hematocrit
Smaller AV prosthesis (value)
Earlier date of operation¶
Late hazard phase
AS alone 3.2 0.76 
ASCAD
ITA graft used (less risk)
Older age*
Myocardial infarction
Larger BMI#
Syncope
Lower ejection fraction** 0.52 0.15
Larger LA diameter††
LV mass index‡‡
Interaction: LA diameter · LV mass index index§§
Interaction: age · LV mass index
Insulin-treated diabetes
Smoking 0.25 0.065 
COPD
Dialysis
Higher BUN¶¶
Lower hematocrit
Any atrial fibrillation procedure
ASD/PFO suture closure
*(Age/75)2, squared transformation. †(100/LV diastolic volume)2, inverse squared transformation.
quared transformation. ¶(1/[interval to date of operation from January 1, 1991]), inverse t
diameter/4.5), scaled variable. ‡‡(LV mass index/125)2, squared transformation. §§Interaction: (
quared transformation.
LA  left atrial; LV  left ventricular; ITA  internal thoracic artery; other abbreviations as in T(26,27), is associated with decreased long-term survival (28),and results in decreased ventricular compliance and
ischemia-induced myocardial fibrosis, contributing to LV
diastolic dysfunction (29,30). Although LV mass index and
LA diameter were smaller in the isolated AS group, these
Procedure
Isolated AS ASCAD
e Coefficient  SE p Value Coefficient  SE p Value
1
0.76 0.25 0.002
0.34 0.16 0.03
0.404 0.18 0.02
0.62 0.27 0.02
1
0.55 0.19 0.004
1
0.34 0.16 0.04
0.64 0.27 0.02
1.02 0.38 0.007
0.097 0.028 0.0004
0.061 0.022 0.006
0.11 0.034 0.002
0.35 0.15 0.02
0.51 0.18 0.005
0.52 0.17 0.002
1.3 0.43 0.003 0.64 0.25 0.01
0.24 0.12 0.05
1.6 0.51 0.002 0.60 0.34 0.08
0.25 0.086 0.004
1.2 0.38 0.001
1
0.24 0.079 0.002
3.7 0.43 0.0001 2.3 0.24 0.0001
0.24 0.082 0.004
0.41 0.11 0.0002
0.34 0.14 0.02
0.86 0.35 0.01 0.34 0.44 0.4
0.73 0.18 0.0001 0.35 0.202 0.09
0.42 0.19 0.03
0.65 0.21 0.002
0.72 0.13 0.0001
1
0.59 0.16 0.0002
1.4 0.303 0.0001
0.14 0.036 0.0002 0.062 0.015 0.0001
0.60 0.18 0.001
0.64 0.20 0.001
0.83 0.26 0.002
DL)2, inverse squared transformation. §(1/creatinine), inverse transformation. (Hematocrit/40)2,
ation. #(BMI/30)2, squared transformation. **(Ejection fraction/55), scaled variable. ††(LA
eter/4.5) · (LV mass index/125)2. Interaction: (age/75)2 · (LV mass index/125)2. ¶¶(BUN/20)2,
and 3.refter
p Valu
0.000
0.000
0.000
0.000
0.001
0.000
‡(50/H
ransform
LA diamfactors, particularly LA diameter (31), are strongly associ-
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patients despite their having larger left heart measures. This
suggests that structural heart changes in the 2 groups are
different. Given the extensive comorbidity profile of the
ASCAD group, secondary effects of more prominent
disease processes, such as hypertension (32), may be respon-
Figure 2 Survival of Propensity-Matched and Unmatched Patien
Survival of patients with isolated AS with few comorbidities (blue triangles) compa
AS (blue diamonds) and ASCAD (red circles). These are all contrasted with patie
pletely unlike that of patients with isolated AS (red squares). Format as in Figure
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Figure 3 Distribution of Propensity Scores
Mirrored histogram of distribution of propensity scores for patients with iso-
lated AS (blue) versus ASCAD (red). Red and blue areas represent 1,082
matched patient pairs. Abbreviations as in Figure 1.sible. Nonetheless, long-term survival of patients with
isolated AS appears to be more sensitive to the presence of
LV hypertrophy and diastolic dysfunction.
Survival comparison. In general, patients with severe AS
and coexisting CAD have worse survival than those with
isolated AS. However, the heterogeneity of patient charac-
teristics makes simple survival comparisons between the 2
groups inaccurate (19). Propensity matching provides an
opportunity to compare outcomes of patients with isolated
AS with those of patients with ASCAD and otherwise
similar non-CAD comorbidity profiles. Matched survival
was similar, consistent with the propensity-matched com-
parison by Roberts et al. (3), suggesting that surgical
revascularization at the time of AVR neutralizes the adverse
effects of CAD, provided that ischemic myocardial damage
has not occurred. However, the distribution of propensity
scores (see Fig. 3) demonstrates that this matched pop-
ulation is an intermediate risk group, different from both
average isolated AS and ASCAD patients. This is
reflected in survival of the unmatched groups. Un-
matched isolated AS patients had better, and ASCAD
patients worse, survival than their respective matched
group. Given the age discrepancies of patients, it is
helpful to reference survival curves to expected U.S.
age-sex-race–matched survival. Isolated AS patients,
both matched and unmatched, had better than expected
survival, as did the matched ASCAD patients (Online
Fig. 6). However, unmatched ASCAD patients have
poor survival, falling below that of the U.S. life table by
8 to 10 years post-operatively.
Patient profile: a determinant of outcomes in severe AS. Pa-
tients’ comorbidity profiles affected survival more than the
Isolated AS, 
few comorbidities
Matched isolated AS
Matched AS+CAD
AS+CAD, 
myocardial
damage, many
comorbidities
ith isolated AS and non–CAD comorbidities matching those of patients with both
aving AS and CAD with myocardial damage and a comorbidity profile that is com-
reviations as in Figure 1.ts
red w
nts h
1. Abbprocedure they underwent. Even in the absence of CAD,
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cluding smoking, vasculopathies, hypertension, diabetes,
and renal disease, had survival equal to matched patients
with CAD who underwent AVRCABG. Unmatched
ASCAD patients had poor survival with a high-risk
comorbidity profile and signs of irreversible ischemic heart
damage. Even if these patients survive surgery, they have
poor survival relative to other patients undergoing the same
procedures. They require chronic disease management for
their comorbidities, as these will ultimately determine their
outcomes. It may be argued whether surgery should be
performed on these patients. The answer may have impli-
cations for future therapies. For example, late results of
transcatheter AVRpercutaneous coronary intervention
may also be determined by patients’ systemic diseases.
Therefore, because of their patient profile, results may not
be as good as those for patients receiving transcatheter AVR
alone (33).
Strengths and limitations. This is a large, contemporary,
single-institution observational study comparing patients
who received either AVR alone for isolated severe AS, or
AVRCABG for severe AS and CAD. All patients were
evaluated by heart catheterization to define coronary artery
STD D
−80 −60 −40
Age
Carotid disease
Hypertension
LA diameter
Blood urea nitrogen
Treated diabetes
NYHA class
LV mass index
Heart failure
LV dysfunction
Peripheral arterial disease
AV stenosis
Female
LV ejection fraction
AV peak gradient
HDL cholesterol
Bicuspid AV
Isolated AS
AS+CAD
Figure 4 Differences Between Unmatched Patients
Standardized differences between unmatched patients with isolated aortic stenosi
AV  aortic valve; HDL  high-density lipoprotein; LA  left atrial; LV  left ventristenosis and underwent primary heart surgery with a singleprosthesis type for isolated degenerative AS. Prior analyses
of these groups evaluated patient risk factors for survival,
which, as both this and other studies noted, are limited
on the basis of the distinct profiles of the patients
undergoing these procedures (6). The application of
propensity analysis enabled direct comparison of a subset
of these patients. Given their similar profiles after match-
ing, patients undergoing surgery for isolated AS and
ASCAD had equal survival and thus no effect of CAD
after intervention.
Diagnosis of CAD was on the basis of catheterization
with at least 1 vessel with stenosis 50%. This definition
was based on clinical practice within our institution for
treatment of CAD, guided by current American Heart
Association and American College of Cardiology recom-
mendations (4). This is reflected in the relatively small
number of patients (n  427) who underwent AVR alone,
but had CAD meeting these criteria; these patients were
excluded from this analysis. Others have applied stricter
criteria, such as 70% to 75% stenosis (34). Only 22 patients
underwent AVRCABG without meeting our criteria for
CAD, but 20 of these procedures were for ostial occlusion
by the prosthesis. Thus, our definition reflects current
ce: Unmatched − Matched (%)
20 0 20 40 60 80
e triangles) group and ASCAD (red squares) group (44).
NYHA  New York Heart Association; other abbreviations as in Figure 1.ifferen
−
s (blu
cular;clinical practice.
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patients with isolated bicuspid valve disease and excellent
expected survival to elderly patients with extensive comor-
bidities resulting in poor functional status and survival.
Therefore, for many patients, AS is not a simple mechanical
disease process, but represents 1 of many concurrent comor-
bidities. Our analysis distinguishes between groups on the
basis of comorbidities and risk factors. These factors should
be used for accurate interpretation of results for current and
future therapies for AS, including percutaneous procedures.
Although patients with isolated AS have excellent sur-
vival, their outcomes are more sensitive to the conse-
quences of long-standing pressure overload leading to LV
hypertrophy and diastolic dysfunction, as reflected by left
atrial size (31,35–37). These results add to evidence that
these patients may need AVR before symptom develop-
ment and irreversible left heart remodeling. In contrast,
those with the highest risk profile have poor survival
because of advanced comorbidities that are not reversed
by AVR.
Complete assessment of patient characteristics should be
incorporated into the decision-making process. In patients
with severe AS and LV hypertrophy, early surgery may be
indicated before symptoms develop. Although current
guidelines for treating valvar heart disease recognize that
risk factors for CAD and AS frequently coexist, there are no
recommendations for early evaluation or diagnosis of CAD
in these patients. Our study demonstrates the devastating
effects on survival of ischemic damage in patients with AS;
this indicates the need for early diagnosis of CAD in these
patients.
The common practice of advocating delay of surgery for
patients with AS in order to avoid anticoagulation associ-
ated with mechanical prostheses can adversely affect long-
term survival because of the potential for myocardial is-
chemic damage. The results of our study strongly suggest
changing practice and modifying guidelines to include early
evaluation of CAD in asymptomatic patients with severe
AS and risk factors for CAD so that timely AVRCABG
is performed before ischemic myocardial damage occurs.
Generally these patients will have reached an age for which
contemporary bioprostheses have lifetime durability in the
great majority (38) and transcatheter valve-in-valve proce-
dures may obviate the need for reoperation in the future
(39–41). Elderly patients with AS and risk factors for CAD
should be considered for active investigation of CAD before
evaluation for AVR. In contrast, patients with poor func-
tional status and advanced comorbidities may be best served
with medical management alone.
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